NEW YORK — Caris Life Sciences has signed an agreement to help identify patients with NTRK fusion-driven cancers for enrollment in an ongoing clinical trial of Pyramid Biosciences' next-generation TRK inhibitor PBI-200, the companies said on Thursday.
PBI-200 is a central nervous system-penetrant selective inhibitor of TRK kinase under development in a Phase I/II study in patients with NTRK fusion-positive advanced or metastatic tumors including primary and metastatic CNS tumors.
Under the terms of their deal, the companies will use Caris' whole-transcriptome and whole-exome sequencing platform and right-in-time clinical trial solution to help find patients who are eligible for enrollment in the clinical trial.
Financial and other terms were not disclosed.
"Caris' patient identification and matching service is invaluable for enabling the development of novel precision therapies, especially in genetically defined populations like NTRK," Pyramid CEO Brian Lestini said in a statement.
In December, Irving, Texas-based Caris struck a deal to help Redx Pharma boost patient accrual in a Phase II trial of an investigational colorectal cancer treatment.